Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
"This agreement will make it possible to speed up the delivery of our malaria and TB vaccines to the people in need, and makes it realistic to do so on the mass scale required," said Jaap Goudsmit, Chief Scientific Officer at Crucell. "It also opens the way for Crucell to speed up the Ebola program with the VRC, which has recently entered a phase I clinical trial. But most importantly, it brings the reality of vaccines such as these significantly closer."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.